TWST - Twist Bioscience Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
30.34
+0.49 (+1.64%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close 29.85
Open 30.24
Bid 0.00 x 1100
Ask 0.00 x 800
Day's Range 29.46 - 32.00
52 Week Range 12.38 - 34.46
Volume 97,977
Avg. Volume 69,200
Market Cap 850.063M
Beta (3Y Monthly) N/A
PE Ratio (TTM) N/A
EPS (TTM) -11.10
Earnings Date N/A
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 28.50
Trade prices are not sourced from all markets
  • Business Wire 5 days ago

    Twist Bioscience to Report Fiscal 2019 Second Quarter Financial Results on Tuesday, April 30, 2019

    Twist Bioscience Corporation (TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA, today announced that it will issue its financial results for the fiscal 2019 second quarter ended March 31, 2019, following the close of market on Tuesday, April 30, 2019. The company plans to hold a conference call and live audio webcast for analysts and investors at 4:30 p.m. Eastern Time to discuss its financial results and provide an update on the company’s business. The press release with the financial results will be accessible from the company’s website prior to the conference call through the Investor Relations section under the “Company” tab at www.twistbioscience.com.

  • Business Wire 8 days ago

    Twist Bioscience and iGEM Partner to Provide Synthetic DNA for iGEM Competition and Registry

    Twist Bioscience Corporation (TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and the International Genetically Engineered Machine (iGEM) Foundation today announced a collaboration to change the way iGEM Competition teams contribute to the Registry of Standard Biological Parts, a free online database for synthetic biologists. A standard biological part is a functional unit of DNA that encodes for a specific biological function (such as a response to stimuli, or the synthesis of interesting proteins), and conforms to a construction standard. Parts from the Registry can be mixed and matched to build synthetic biology devices and systems.

  • Business Wire 12 days ago

    Twist Bioscience Announces Antibody Optimization Agreement with Pandion Therapeutics

    Twist Bioscience Corporation (TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a new collaboration with Pandion Therapeutics, to apply its antibody optimization platform to the targeting arm of a bispecific antibody. Pandion Therapeutics is a biotechnology platform company developing therapeutics to achieve localized immunomodulation to treat autoimmune and inflammatory disease.

  • Twist Bioscience (TWST) Looks Good: Stock Adds 6.5% in Session
    Zacks 13 days ago

    Twist Bioscience (TWST) Looks Good: Stock Adds 6.5% in Session

    Twist Bioscience (TWST) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

  • Business Wire 14 days ago

    Twist Bioscience Customized Libraries for Biologics Discovery Highlighted at PEGS Boston 2019

    - Proof-of-Concept Data Presented for GPCR Library and Antibody Optimization Solution –

  • Business Wire 14 days ago

    Twist Bioscience Adopts Battelle’s ThreatSEQ™ DNA Screening Web Service for Advanced Biosecurity

    Twist Bioscience Corporation (TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it is the first to implement Battelle’s ThreatSEQ™ web service DNA screening platform for the detection and characterization of sequences of concern in genomic data, supplementing its internal biosecurity efforts. “We have spent decades working with and characterizing biothreats to support global biodefense efforts, which has resulted in the curation of a high-quality Sequence of Concern database and the development of a robust algorithm for screening DNA at production scale rapidly,” said Matt Vaughan, President of Battelle’s Contract Research business.

  • Business Wire 19 days ago

    Twist Bioscience and LakePharma Form Strategic Collaboration to Provide Antibody Discovery and Development Services

    Twist Bioscience Corporation (TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and LakePharma, Inc., the leading US-based biologics CRDMO, today announced a strategic collaboration to offer antibody discovery and development solutions to pharmaceutical and biotechnology customers. Under the terms of the agreement, LakePharma will have the ability to offer Twist’s proprietary antibody discovery and optimization platforms to their existing and future biopharmaceutical customers as part of their service offerings. One such platform generated is for discovery of novel therapeutic antibodies against a major class of protein drug targets known as GPCRs, which traditionally have been difficult for biologics drug development.

  • Business Wire 22 days ago

    Twist Bioscience Announces Presentations and User Group Meeting at PEGS Boston 2019

    -- Aaron Sato, Ph.D., Chief Scientific Officer of Twist Biopharma, to Deliver Keynote Address –

  • Business Wire 2 months ago

    Twist Bioscience to Present at Cowen 39th Annual Healthcare Conference

    Twist Bioscience Corporation (TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder, will present at the 39th Annual Cowen Healthcare Conference on Tuesday, March 12th at 11:20 a.m. Twist Bioscience is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip.

  • Twist Bioscience Showcases Next-Generation Sequencing Solutions at the 2019 Advances in Genome Biology and Technology Meeting
    Business Wire 2 months ago

    Twist Bioscience Showcases Next-Generation Sequencing Solutions at the 2019 Advances in Genome Biology and Technology Meeting

    -- New Features Enable Sample to Sequencer in a Single Day –

  • Associated Press 2 months ago

    Twist Bioscience: Fiscal 1Q Earnings Snapshot

    The San Francisco-based company said it had a loss of $1.18 per share. The maker of synthetic DNA for the biotechnology industry posted revenue of $11.5 million in the period, surpassing Street forecasts. ...

  • Business Wire 2 months ago

    Twist Bioscience Reports First Quarter Fiscal 2019 Financial Results and Highlights Commercial and Operational Progress

    -- Reports Record Revenue of $11.5 Million for First Quarter of Fiscal 2019 --

  • Business Wire 2 months ago

    Twist Bioscience Announces Appointment of Martin Kunz as Senior Vice President, Operations

    Twist Bioscience Corporation (TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA manufactured on its silicon platform, today announced the appointment of Martin Kunz as senior vice president of operations.

  • Business Wire 3 months ago

    Twist Bioscience Chief Technology Officer Presented at Praesens Foundation Future Health Threats Initiative 2019

    Twist Bioscience Corporation (TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA, today announced that Bill Peck, Ph.D., chief technology officer, participated in the Future Health Threats Initiative 2019, a conference designed to encourage public-private cooperation to strengthen health security in Africa. The Praesens Foundation is operating at the intersection of global health technology innovation and social impact.

  • What's next for this slow-moving Peninsula biotech IPO?
    American City Business Journals 3 months ago

    What's next for this slow-moving Peninsula biotech IPO?

    The company filed in late September for a $75 million initial public offering but has yet to release any more information, even as a key partnership hits major milestones.

  • Business Wire 3 months ago

    Twist Bioscience to Report Fiscal 2019 First Quarter Financial Results on Thursday, February 7, 2019

    Twist Bioscience Corporation (TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA, today announced that it will issue its financial results for the fiscal 2019 first quarter ended December 31, 2018, following the close of market on Thursday, February 7, 2019. The company plans to hold a conference call and live audio webcast for analysts and investors at 4:30 p.m. Eastern Time to discuss its financial results and provide an update on the company’s business. The call can be accessed by dialing (866) 688-0947 (domestic) or (409) 217-8781 (international) and refer to the conference ID 7382069.

  • Business Wire 3 months ago

    Twist Bioscience Receives ISO 13485:2016 and 9001:2015 Certifications of its Quality Management Systems for NGS Target Enrichment Panels

    Twist Bioscience Corporation (TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA, today announced that its quality management systems for manufacturing its next-generation sequencing (NGS) Target Enrichment Panels received International Organization for Standardization (ISO) 9001:2015 and 13485:2016 certification1, the latter for medical device applications. Twist Bioscience offers NGS Solutions including Twist Custom Panels and Twist Human Core Exome Kits.

  • American City Business Journals 3 months ago

    8 of the 10 biggest Q4 startup exits in Bay Area came from IPOs in October

    Exits from the region last quarter were valued at about $56 billion, a total topped just twice this century — in 2014 when the total was nearly $69 billion and 2012 when it was nearly $94 billion.

  • Government shutdown may mean an IPO-less January
    American City Business Journals 3 months ago

    Government shutdown may mean an IPO-less January

    The partial closure of the Securities and Exchange Commission due to the stalemate over building a wall at the southern U.S. border is forcing companies that were seeking to list shares in January to push back their plans.

  • Business Wire 3 months ago

    Twist Bioscience Enhances Genes Product Offering with Longer Genes and Offers Access to Its Application Programming Interface

    Twist Bioscience Corporation (TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA, today announced it has expanded its product portfolio to offer genes up to five kilobases (5kb) in length at industry-leading pricing. In addition, Twist is making its Application Programming Interface (Twist API or TAPI) available for all customers ordering genes.

  • Business Wire 4 months ago

    Twist Bioscience to Present at the 37th Annual J.P. Morgan Healthcare Conference

    Twist Bioscience Corporation (TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA, today announced that Emily Leproust, Ph.D., CEO and co-founder, will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9th at 1:30 p.m. Pacific Time in San Francisco. Twist Bioscience is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip.

  • GuruFocus.com 4 months ago

    Twist Bioscience Corp (TWST) Files 10-K for the Fiscal Year Ended on September 30, 2018

    For the last quarter Twist Bioscience Corp reported a revenue of $10.8 million, compared with the revenue of $2.27 million during the same period a year ago. The Twist Bioscience Corp had an operating margin of -277.5%, compared with the operating margin of -543.16% a year before. The 10-year historical median operating margin of Twist Bioscience Corp is -1233.59%.

  • Business Wire 4 months ago

    Twist Bioscience Reports Fiscal 2018 Fourth Quarter and Full Year Financial Results and Highlights Commercial and Operational Progress

    – $25.4 million in total revenue; 136% year-over-year growth –

  • Here's Why Twist Bioscience Stock Soared 89% in November
    Motley Fool 4 months ago

    Here's Why Twist Bioscience Stock Soared 89% in November

    The DNA synthesis leader had a great month following its IPO.

  • Business Wire 5 months ago

    Twist Bioscience to Report Fiscal 2018 Fourth Quarter and Full Year Financial Results on Wednesday, December 19, 2018

    Twist Bioscience Corporation (TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA, today announced that it will issue its financial results for the fourth quarter and fiscal year ended September 30, 2018 following the close of market on Wednesday, December 19, 2018. The company plans to hold a conference call and live audio webcast for analysts and investors at 4:30 p.m. Eastern Time to discuss its financial results and provide an update on the company’s business. The call can be accessed by dialing (866) 688-0947 (domestic) or (409) 217-8781 (international) and refer to the conference ID 8279646.